BACKGROUND:: There are limited studies investigating the relationship between oral release osmotic system- @entity2727 (OROS-MPH) doses and plasma @entity2727 ( @entity7541 ) concentrations in @entity1 and adolescents. The aim of the present study was to investigate the relationship between the doses of OROS- @entity7541 and the plasma levels of the drug. We also examined the effects of the other drugs including @entity1770 , @entity1090 , @entity905 , and @entity3756 on the levels of the @entity7541 in the plasma. METHODS:: The files of 100 @entity71 subjects (76 male, 24 female) who were diagnosed as @entity71 according to the DSM-IV criteria, were screened. The ages of subjects were between 6-18 years (mean= 11.5  3.8 years). Plasma @entity7541 levels were determined by @entity3928 ( @entity3928 ). RESULTS:: Daily mean OROS @entity7541 dose used in @entity71 @entity1 was 0.7  0.2 mg/kg (range: 0.3-1.3 mg/kg). The mean plasma OROS @entity7541 was 11.6    7.3 ng/mL (range: 0.5-43.4 ng/mL). There was no group difference in the mean plasma @entity7541 and dose-related @entity7541 levels between the groups that used any additional drug including @entity1770 (n=25), @entity1090 (n=10), @entity905 (n=16) @entity3756 (n=10) and not used these drugs (p>.05). There was a positive correlation between the OROS @entity7541 doses (mg/kg) and the blood @entity7541 levels (Pearson correlation= 0.40; p<.001). The plasma levels of @entity7541 were found to be less than 13 ng/mL in 65% of the subjects. CONCLUSIONS:: Our findings point to the fact that plasma levels of @entity7541 show a wide range of changes at similar doses, correlate positively with the doses and, as expected, are not affected by using @entity1090 , @entity3756 , @entity905 , and @entity1770 . Therapeutic drug monitoring (TDM) may help to optimize @entity7541 dose in @entity1 not responding to treatment or in those experiencing serious side effects, but not in routine clinical practice. The presence of intermediate dose formulations such as 45 mg tablets for OROS @entity7541 may contribute to the optimization.

Plasma @entity2727 Levels In Youths with Attention XXXX Treated with OROS Formulation.

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine'] @entity3928 :: ('MESH:C536030', 'Disease') :: ['high-performance liquid chromatography-tandem mass spectrometry assay', 'HPLC-MS/MS'] @entity71 :: ('MESH:D001289', 'Disease') :: ['ADHD'] @entity7541 :: ('MESH:C041626', 'Chemical') :: ['MPH'] @entity3756 :: ('MESH:D020280', 'Chemical') :: ['sertraline'] @entity1770 :: ('MESH:C094645', 'Chemical') :: ['aripiprazole'] @entity2727 :: ('MESH:D008774', 'Chemical') :: ['methylphenidate'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']
@entity71 :: (MESH:D001289,Disease) :: ['Deficit Hyperactivity Disorder']
